Wall Street is neutral on Adverum Biotechnologies Inc (ADVM). On average, analysts give the stock a Buy rating. The average price target is $6, which means analysts expect the stock to increase by 219.15% over the next twelve months. That average ranking earns the stock an Analyst Rating of 13, which is better than 13% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating ADVM a Buy today. Find out what this means to you and get the rest of the rankings on ADVM!